drugset / Trial / NCT02537054
Intravitreal Aflibercept for Therapy of Patients With Pseudoxanthoma Elasticum (PXE)
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether Aflibercept (Eylea) is effective in the treatment of choroidal neovascularization and fibrovascular proliferation in patients with pseudoxanthoma elasticum (PXE) in terms of preservation or improvement of visual acuity.
Timeline
- Start
- 2015-09
- Primary completion
- 2018-07-02
- Completion
- 2018-07-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aflibercept | Protein / enzyme biologic | 2 mg | Intravitreal |